# Huiyan Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/huiyan-bio

- Industry: Biotechnology
- Headquarters: Wuhan, China
- Website: www.huiyan-bio.com
- Latest round: Series A (Nov 26, 2020)
- Investors on record: 1

## About

Based in Wuhan, China, and established in 2013, Huiyan Bio operates as a biotechnology company that focuses on providing mediums and equipment used in separation and purification. The company passed the ISO9001 system certification and was recognized as the National High-tech Enterprise. It also acquired 6 invention patents. In November 2020, Huiyan Bio closed series A funding from new investor Greenriver Capital.

Huiyan Bio mainly provides technical services such as protein, antibody, peptide, and nucleic acid isolation and purification. The company mainly provides gel filtration, ion exchange, and hydrophobic chromatography media, and chromatography columns. Agarose gel filtration medium, Focurose 4B, is suitable for the separation of components and medium purification of biomolecular substances, such as virus particles and recombinant hepatitis B surface antigen. Its products and services can be used in biotechnology, biopharmaceuticals, diagnostic reagents, biologics, and medical devices.

## Funding rounds

- Series A, Nov 26, 2020 — Greenriver Capital

## Investors

- Greenriver Capital (https://capitalatlas.ai/funds/greenriver-capital) — Series A